JOURNALS

Question 1

Main sites of gastric ulcer

Answer 1

Gastric angle, hiatal hernia, cardia, and gastric antum

Question 2

Agent responsible for gastric ulcer

Answer 2

Helicobacter Pylori

Question 3

Main clinical manifestation of gastric ulcer

Answer 3

Epigastric pain, dull pain, dull pain and burning sensation

Question 4

The control group with gastric ulcer was treated with? (with dosage)

Answer 4

Omeprazole (2x a day, 20 mg each)

Question 5

The experimental group with gastric ulcer was treated with? (with dosage)

Answer 5

Omeprazole + Amoxicillin (500 mg, x3 a day)

Question 6

A patient with gastric ulcer and bleeding needs drug that are ?

Answer 6

Proton pump inhibitor or H2 receptor antagonist for hemostatic treatment

Question 7

Experience group with gastric ulcer (n, remarkable effect, effective, invalid, total effective rate)

Answer 7

n = 44
Remarkable effect = 28
effective = 15
Invalid = 1
Total effective rate = 97.73

Question 8

JOURNAL TITLE: Efficacy and ___ of ____ and ___ in the treatment of ____

Answer 8

Safety, Omeprazole, Amoxicillin, Gastric Ulcer

Question 9

C positive rate of breath test in experimental group (n, before, after treatment)

(Gastric ulcer patients)

Answer 9

n = 44
Before treatment = 40
After treatment = 10

Question 10

Control group (people with gastric ulcer) n, remarkable effect, Effective, Invalid, total effective rate

Answer 10

n = 44
remarkable effect = 24
effective = 13
Invalid = 7
total effective rate rate = 84.09

Question 11

C positive rate of breath test in control group (n, before, after treatment)

(Gastric ulcer patients)

Answer 11

n = 44
before treatment = 38
After treatment = 21

Question 12

Recurrence rate in control group (patients with gastric ulcer)

Answer 12

9

Question 13

Recurrence rate in control group (patients with gastric ulcer)

Answer 13

2

Question 14

It is a proton pump inhibitor drug that can decrease gastric acid secretion, avoid the degradation of blood clots in gastric ulcers

Answer 14

Omeprazole

Question 15

Belongs to semi-synthetic penicillin, broad-spectrum antibiotic

Answer 15

Amoxicillin

Question 16

Aggressive factors in Gastric Ulcer

Answer 16

HCl, Pepsin, gastric Acid

Question 17

Protective factors in Gastric Ulcer

Answer 17

Mucus and Bicarbonate ions

Question 18

Plays an important role in the synthesis of glycopeptides and construction of cell wall

Answer 18

Transpepitdation

Question 19

Two times verus __ times daily ___ Dosing for the treatment of ___ in Females

Answer 19

Four, Cephalexin Uncomplicated Urinary Tract Infections

Question 20

One of the most common indications for outpatient antibiotic prescribing

Answer 20

Urinary Tract Infections

Question 21

Infectious Disease Society of America recommended the treatment of uncomplicated UTI with the following drugs: (first line empiric therapies

Answer 21

Trimethoprimsulfamethoxazole, nitrofurantoin, fosfomycin

Question 22

An oral first-generation cephalosporin

Answer 22

Cephalexin

Question 23

Bioavailability of Cephalexin

Answer 23

90%

Question 24

Common recommended dosage of cephalexin

Answer 24

250mg to 500mg every 6 hours (but 12 hours is adequate)

Question 25

Defined as Antibiotic treatment received at discharge from emergency department, urgent care site, or medical group office

Answer 25

Outpatient setting

Question 26

Serves as a surrogate for cephalexin susceptibility

Answer 26

Cefazolin

Question 27

Cefazolin susceptibility was determined by automated methods with the ?

Answer 27

Vitek 2 System (bioMerieux)

Question 28

Patients received cephalexin 500 mg 2 times a day or 4 times a day for 5 to 7 days as per the ?

Answer 28

ICD-10 diagnosis code for UTI

Question 29

Defined as the combined endpoint of (1) continued symptoms or necessitation of new therapy while taking the initially prescribed 5 to 7 days of treatment and (2) treatment of recurrent symptomatic UTI within 30 days

Answer 29

Treatment failure

Question 30

Primary objective of the study regarding 2 times and 4 times Cephalexin daily dosing

Answer 30

Compare treatment failure between patients treated for uUTI in the outpatient setting with oral cephalexin

Question 31

Is there any difference in the primary outcome of treatment failure between 2 groups of cephalexin?

Answer 31

No difference

Question 32

Most common adverse event reported in both groups of patients with UTI

Answer 32

Yeast infection

Question 33

Major benefit of reducing frequency of cephalexin for uUTI is?

Answer 33

Potential to improve patient adherence and satisfaction with treatment

Question 34

Oral ___/___ for the prevention of ___ following dental ___

Answer 34

Amoxicillin/Clavulanate, bacteremia, extractions

Question 35

A disease with an estimated annual incidence of 3-10 cases per 100,000 individuals and is characterized by high morbidity and mortality

Answer 35

Infectious endocarditis

Question 36

Mainly produced in relation to basic activities of daily life such as toothbrushing, odontogenic infections, and dental therapeutic procedures

Answer 36

Oral bacteremia

Question 37

Antibiotic of choice for patients who are not allergic to beta-lactams

Answer 37

Amoxicillin

Question 38

to determine the prevalence and duration of the bacteremia, ___ of peripheral venous blood was collected

Answer 38

10 ml

Question 39

The AMXG was given amoxicillin __ hours before the surgery

Answer 39

1-2 hours

Question 40

Most common pathogens in the oral cavity and responsible for most oral-maxillofacial infections

Answer 40

Staphylococcus aureus and Streptococcus viridans

Question 41

Primary cause of Infectious Endocarditis of oral origin

Answer 41

Streptococcus viridans

Question 42

It is a rare opportunistic infection but is associated with high mortality and morbidity

Answer 42

Mucormycosis

Question 43

Most common site of infection of mucormycosis

Answer 43

rhino-orbital-cerebral followed by pulmonary.

Question 44

It is a life threatening condition caused by Rhizopus microsporus.

Answer 44

Pulmonary mucormycosis

Question 45

Causative agent of pulmonary mucormycosis

Answer 45

Rhizopus microsporus

Question 46

what kind of diabetes did the patient with pulmonary mucormycosis have and how long did he have it?

Answer 46

Type 2 diabetes (2 years)